Jefferies downgraded Verve Therapeutics (VERV) to Hold from Buy with a price target of $11, down from $28, after Eli Lilly (LLY) announced a definitive agreement to acquire Verve. Lilly will commence a tender offer to acquire all of the outstanding shares of Verve for a purchase price of $10.50 per share in cash, an aggregate of approximately $1B, plus one non-tradeable contingent value right per share that entitles the holder to receive up to an additional $3.00 per share. Lilly “appears to be good suitor,” given the existing partnership across the pipeline, the analyst tells investors in a research note. It sees likely Federal Trade Commission approval for the takeover.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics downgraded to Market Perform from Outperform at LifeSci
- Hold Rating on Verve Therapeutics Amid Acquisition and Development Milestones
- Verve Therapeutics downgraded to Hold from Buy at Canaccord
- Verve Therapeutics downgraded to Market Perform at William Blair
- Morning Movers: Verve skyrockets after deal to be acquired by Eli Lilly